Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

HUTCHMED (HCMN) Stock Price & Analysis

HCMN Stock Chart & Stats

No data to display
Day’s Range
N/A
52-Week Range
N/A
Previous Close
N/A
Volume
N/A
Average Volume (3M)
N/A
Market Cap
MXN 43.42B
Enterprise Value
MXN 612.26M
Total Cash (Recent Filing)
MXN 1.38B
Total Debt (Recent Filing)
MXN 94.51M
Price to Earnings (P/E)
143.2
Beta
N/A
Next Earnings
Mar 04, 2027 (Est.)
EPS Estimate
3.78
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Conservative Balance Sheet

Very low leverage gives HUTCHMED financial flexibility to fund research, development and commercialization without substantial debt servicing pressure. A solid equity base also improves resilience if operating losses persist or pipeline investment needs remain elevated over the next several quarters.

Regulatory Pipeline Progress

Acceptance of the Orpathys and Tagrisso filings advances a partnered oncology program toward potential approvals in two important markets. While review is not approval, the step expands the program’s commercial opportunity and supports HUTCHMED’s global development and licensing model.

Modest Revenue Growth

Positive trailing-twelve-month revenue growth indicates that HUTCHMED’s marketed products and collaboration activities are generating some expansion despite uneven profitability. Continued top-line progress can provide a broader base for commercial leverage and help support investment in the oncology pipeline.

Bears Say

Negative Core Profitability

Persistently negative operating margins show that the core business is not yet converting revenue into sustainable operating profit. This can limit internally funded growth, increase dependence on product uptake or partners, and make future earnings more sensitive to development and commercialization spending.

Low Earnings Quality

Strong reported net income alongside operating losses indicates that earnings may not reflect recurring performance from products and collaborations. If non-operating contributors do not repeat, headline profitability could weaken, making results less reliable for assessing the company’s durable earnings power.

Volatile Cash Generation

Large swings in free cash flow reduce visibility into HUTCHMED’s ability to fund research and commercial expansion consistently. Although the latest period improved, renewed investment requirements or operating weakness could again produce cash outflows and constrain capital allocation flexibility.

HUTCHMED News

HCMN FAQ

What is HUTCHMED’s market cap?
HUTCHMED’s market cap is Mex$43.42B.
When is HUTCHMED’s upcoming earnings report date?
HUTCHMED’s next earnings report is estimated for Mar 04, 2027 (not yet confirmed), which is in 122 days.
How were HUTCHMED’s earnings last quarter?
HUTCHMED released its earnings results on Jul 30, 2026. The company reported Mex$1.798 earnings per share for the quarter, missing the consensus estimate of Mex$2.607 by -Mex$0.809.
Is HUTCHMED overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does HUTCHMED pay dividends?
HUTCHMED does not currently pay dividends.
What is HUTCHMED’s EPS estimate?
HUTCHMED’s EPS estimate is 3.78.
How many shares outstanding does HUTCHMED have?
HUTCHMED has 174,467,030 shares outstanding.
What happened to HUTCHMED’s price movement after its last earnings report?
HUTCHMED reported an EPS of Mex$1.798 in its last earnings report, missing expectations of Mex$2.607. Following the earnings report the stock price went same ―.
Which hedge fund is a major shareholder of HUTCHMED?
Hedge funds hold HUTCHMED shares: hedge funds decreased their holdings by 110.4K shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology